Maddy summaryThe PROVE IT Act of 2024 directs the U.S. Energy Secretary to study and publicly report on the greenhouse gas emissions intensity of key U.S. manufactured products (like steel, aluminum, lithium batteries, and critical minerals) compared to those produced in "covered countries" (including the EU, China, and major trading partners). It requires a transparent methodology for calculating emissions data, identifies gaps in existing data, and establishes a public online database showing U.S. emissions advantages for these products. The bill also mandates an annual report on foreign countries using forced labor or human rights abuses in the production of critical minerals or rare earths. Importantly, it clarifies the study does not create new taxes, fees, or mandatory reporting requirements.
Rep. Scott H. Peters
Sponsored bills
Maddy summaryThis bill requires Medicare Advantage plans to implement electronic prior authorization systems by 2027 and publish detailed data on their approval and denial rates for medical services by 2026. It directly affects Medicare Advantage plans (private insurers offering Medicare coverage) and their enrollees (seniors 65+), mandating transparency about prior authorization decisions, processing times, and appeal outcomes. Key provisions include requiring plans to report annual statistics on request approvals/denials, average processing times, and use of technology, with this data published publicly by the Centers for Medicare & Medicaid Services. The bill also sets timelines for plan responses to prior authorization requests and mandates reports to Congress on implementation and impacts.
Maddy summaryThe ROCR Value Based Program Act establishes a new Medicare payment system for radiation oncology services, replacing the current fee-for-service model with a per-episode payment structure. This program affects radiation therapy providers (hospital outpatient departments) and suppliers (physician practices or freestanding centers) treating Medicare beneficiaries with specific cancer types (including breast, prostate, lung, and brain metastases). Key provisions include 80% of the payment being paid upfront within 30 days of treatment start, with the remaining 20% paid later; a health equity add-on payment of $500 per patient for transportation services to patients reporting transportation insecurity (using ICD-10 code Z59.82); and quality incentives for accredited providers through a 0.5% payment increase for meeting accreditation requirements. The program aims to stabilize payments, improve access to radiation therapy, enhance quality, leverage technology, and contain costs while maintaining Medicare savings.
Maddy summaryThe Essential Caregivers Act of 2024 requires nursing homes and similar facilities to allow residents to designate essential caregivers who provide emotional support or assistance with daily activities. During emergencies when regular visitation is restricted, facilities must permit at least one essential caregiver access to residents daily and cannot deny access without following specific procedures. Facilities may deny access for a maximum of 7 days during emergencies (or 14 days with state approval), and must provide a written explanation and appeal process if access is denied. The bill establishes a 48-hour appeal process for residents and caregivers to challenge denials, with facilities required to prove violations during appeals. This law applies to Medicare skilled nursing facilities, Medicaid nursing facilities, intermediate care facilities, and certain inpatient rehabilitation facilities.
Maddy summaryHR 8137 would remove a 1997 federal restriction that blocks funding for medical aid-in-dying services. Starting January 1, 2025, it allows federal programs (like veterans' healthcare) to cover information, referrals, or care related to medical aid-in-dying in states that have legalized the practice. This directly affects terminally ill patients in states with existing laws (like Oregon, California, or Washington), enabling them to access federal-funded support for this option. The bill clarifies it does not change the definition of medical aid-in-dying as distinct from euthanasia or assisted suicide.
Maddy summaryHR 7142 (Alternatives to PAIN Act) requires Medicare Part D plans to cover non-opioid pain management drugs with no deductible and at the lowest copay level starting in 2025. It defines "qualifying non-opioid drugs" as FDA-approved medications that don’t act on opioid receptors (like certain NSAIDs or nerve pain treatments), excluding opioids and schedule I-III drugs. The bill prohibits Medicare plans from forcing patients to try opioids first (step therapy) or requiring prior approval for these non-opioid options. It directly affects Medicare beneficiaries needing pain management, especially those seeking alternatives to opioids for post-surgical or acute pain. The policy change aims to improve access to non-addictive pain treatments while preserving doctors' authority to prescribe medically appropriate care.
Maddy summaryHR 6780 establishes a 4-year Medicare demonstration program testing whether hospitals providing medically tailored home-delivered meals to specific patients improves health outcomes and reduces hospital readmissions. The program targets Medicare beneficiaries with diet-sensitive chronic conditions (like diabetes or heart failure) who are at high risk of readmission and meet specific discharge criteria, such as limited daily living activities. Selected hospitals must screen patients, provide at least two tailored meals daily for 12 weeks, and offer medical nutrition therapy, all without patient cost-sharing. The program requires hospitals to submit data for evaluation, with the goal of assessing impacts on hospital admissions, care costs, and patient satisfaction before reporting to Congress in 2027 and 2030.
Maddy summaryHR 6790 establishes National Institutes of Health centers to advance research, early detection, and public awareness of rare kidney diseases, with a focus on rural and underserved communities. It mandates a federal study on genetic testing barriers, treatment patterns, and public awareness for rare kidney diseases affecting disproportionately impacted populations, including barriers to insurance coverage and access to specialists. The bill also funds nephrology training programs to increase specialists serving these communities and requires experiments to delay or prevent the need for dialysis and transplants. Total funding of $7 million is authorized for fiscal years 2024-2028 to support these research, education, and early intervention efforts.
Maddy summaryHR 6465, the PLASMA Act, amends Medicare Part D's discount program to create a specific phase-in for plasma-derived specialty drugs. It directly affects Medicare Part D beneficiaries who use these drugs and reach their annual out-of-pocket spending limit. The bill establishes a new "specified plasma-derived product percent" to calculate discounted prices for these drugs, based on whether beneficiaries have already met their out-of-pocket threshold for other Part D drugs. This changes how manufacturers' negotiated prices are discounted for plasma-derived products under the existing program, without creating new benefits or altering coverage.
Maddy summaryHR 5744, the Energy Innovation and Carbon Dividend Act of 2023, would impose a carbon fee on fossil fuels (crude oil, coal, and natural gas) based on their greenhouse gas emissions, starting at $15 per metric ton of CO2 equivalent in 2023 and increasing by $10 annually. The revenue from this fee would be distributed directly to American citizens as monthly "carbon dividends" through a new trust fund, with adults receiving full payments and children under 19 receiving half payments. The bill also establishes a border fee adjustment on imported carbon-intensive products to prevent companies from moving operations to countries with weaker environmental regulations. It sets specific emissions reduction targets: 8% annual reductions from 2025-2030 and 2.5% annual reductions from 2031-2050 relative to 2005 levels. The carbon fee would be phased out once emissions drop to 10% of 2005 levels and monthly dividends fall below $20 for three consecutive years.